Calcium Chloride
drugOn this page
Also known as BovikalcCacl2Cacl2 (anhydrous)Calcarea muriaticaCalcium chloride anhydrousCalcium chloride component of navstelCalcium chloride dihydrateCalcium chloride hydrateCalcium chloride solutionanhydrousDowflakeE-509E509INS NO.509INS-509Intergravin-oralesKalganLiquidowNSC-759598
Summary
Calcium Chloride (CHEMBL1200668) is an approved small molecule (ATC G04BA03); indicated across 11 conditions including basal cell carcinoma and atrial fibrillation.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: G04BA03 (+2 more)
- Indications: 11 conditions
- Clinical trials: 14
- Chemistry: 110.98 Da · CaCl2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200668 |
| Name | Calcium Chloride |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5284359 |
| ChEBI | CHEBI:3312 |
| ATC | G04BA03, B05XA07, A12AA07 |
| Molecular formula | CaCl2 |
| Molecular weight | 110.98 |
| InChIKey | UXVMQQNJUSDDNG-UHFFFAOYSA-L |
SMILES: [Cl-].[Cl-].[Ca+2]
IUPAC name: calcium dichloride
Other ChEBI roles (chemical / environmental): fertilizer, NMR chemical shift reference compound.
Also known as: Bovikalc, Cacl2, Cacl2 (anhydrous), Calcarea muriatica, Calcium chloride, Calcium chloride anhydrous, Calcium chloride component of navstel, Calcium chloride dihydrate, Calcium chloride hydrate, Calcium chloride solution, anhydrous, Dowflake
Parent form; salt/anhydrous children: CHEMBL2106539, CHEMBL2107795
Patent coverage: 250,014 distinct patent families (573,274 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 573,207 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| basal cell carcinoma | 3 | MONDO:0020804 | EFO:0004193 |
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| cardiac arrest | 2 | MONDO:0000745 | EFO:0009492 |
| keloid | 1 | MONDO:0005348 | EFO:0004212 |
| head and neck cancer | 1 | MONDO:0005627 | EFO:0006859 |
| osteoporosis | 0 | MONDO:0005298 | EFO:0003882 |
| vascular disorder | 0 | MONDO:0005385 | EFO:0004264 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE4 | 2 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 2 |
| Not specified | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00955266 | PHASE4 | TERMINATED | A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass |
| NCT03772990 | PHASE4 | COMPLETED | Calcium Administration in Cardiac Surgery |
| NCT05027048 | PHASE3 | COMPLETED | Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery |
| NCT05046262 | PHASE3 | UNKNOWN | Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study |
| NCT06378021 | PHASE3 | UNKNOWN | Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG |
| NCT07550413 | PHASE2 | NOT_YET_RECRUITING | Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section |
| NCT03867383 | PHASE1/PHASE2 | COMPLETED | Calcium Chloride for Prevention of Uterine Atony During Cesarean |
| NCT04153435 | PHASE2 | COMPLETED | Calcium for Out-of-Hospital Cardiac Arrest |
| NCT01941914 | PHASE1 | COMPLETED | Calcium Electroporation for the Treatment of Keloids |
| NCT03051269 | PHASE1 | UNKNOWN | Calcium Electroporation for Head and Neck Cancer |
| NCT03719001 | EARLY_PHASE1 | COMPLETED | Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study |
| NCT05973747 | EARLY_PHASE1 | COMPLETED | Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients |
| NCT07187544 | Not specified | RECRUITING | Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery |
| NCT02580604 | Not specified | COMPLETED | PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: basal cell carcinoma, atrial fibrillation